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 POSTER PRESENTATIONS 
 Advances in Pain Management 
 Buffered dextrose 5% – an alternative analgesia 
 M. L. Swee 1  , H. E. Liu 1 , Y. Y. Jasmine Sze 1 , H. N. Kooi 1 , H. C. Siew 1 , 
S. Shantene 1 , M. Nadiah 1 , M. Asmah 1 , C. G. Suk 1  
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 Background/Purpose: Chronic pain around neck and upper limbs 
(NUL) among patients with rheumatic and musculoskeletal disease 
(RMD) is challenging to handle. Dr John Lyftogt has established the 
use of buffered dextrose 5% with pH of 7.4 (BD5%) in Perineural 
injection therapy (PIT) to treat such condition with success. 
 Our primary objective is to assess pain score reduction (PSR) in 
Numerical Rating scale (NRS) after PIT in this region. Secondary ob-
jective is to assess percentage of patients who achieved at least 50% 
PSR at the end of treatment. 
 Methods: Patients with NUL pain who received PIT in 2019 and 
had followed up for 12 months were reviewed. PIT was performed 
by serial injection of BD5% along the superficial nerve(s) under-
neath the skin using 30G, 1cm hypodermic needle. Patients with 
pain score not recorded or still undergoing PIT were excluded. 
PSR before and after series of treatments were analysed using 
paired T test. 
 Results: 21 patients with NUL pain were treated with total of 61 PIT. 
Mean age was 58.1. 76.2% (n = 16) were female. 57.1% (n = 12) had 
shoulder tendinopathy with or without tear, 33.3% (n = 7) had fibro-
myalgia while 9.5% (n = 2) had cervical spondylosis. 
 Baseline pain score was 7.0 ± 1.4, duration of pain was 1.8 ± 1.6 
years. Average 2.9 ± 1.5 times of PIT were performed. 19% (n = 4) 
had one PIT, 23% (n = 5) needed two while 29% (n = 6) needed three 
PIT. Distribution of cases according to number of PIT as shown in 
Figure 1. 
 Pain score reduced to 2.9 ± 1.7, 2.1 ± 1.4 and subsequently 1.4 ± 1.1 
following first, second and third PIT. On average, PSR was 6.0 ± 2.2 
(p = 0.0001). The effect lasted for 5.7 ± 4.2 months. No complica-
tions were observed. 
 100% of them demonstrated 50% or more PSR. 
 Conclusion: Buffered dextrose 5% in perineural injection therapy al-
leviates NUL pain significantly. This is a good and safe alternative 
treatment for RMD patients with NUL pain. 
 Buffered dextrose 5% - the sweet solution for 
chronic low back pain 
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 Background/Purpose: Chronic low back pain (CLBP) is one of the 
constant struggle among patients with rheumatic and musculoskel-
etal disease (RMD). Dr John Lyftogt had used buffered dextrose 5% 
with pH of 7.4 (BD5%) via caudal epidural injection (CEI) to treat 
CLBP successfully. 
 Our primary objective is to assess pain score reduction (PSR) in 
Numerical Rating scale (NRS) after CEI. Secondary objective is to 
assess percentage of patients who achieved at least 50% PSR at the 
end of treatment. 
 Methods: Patients with CLBP who received CEI in 2019 and had fol-
lowed up for 12 months were reviewed. CEI was performed by giv-
ing 10 mL of BD5% at caudal epidural region via 26G, 1cm needle. 
Patients with pain score not recorded or still undergoing CEI were 
excluded. PSR before and after series of treatments were analysed 
using paired T test. 
 Results: 35 patients received total of 127 CEI for CLBP. Mean age 
was 62.1 years and 80% (n = 28) were females. 80% (n = 28) had 
mechanical low back pain due to spondylosis, prolapsed interver-
tebral disc, spinal stenosis and spondylolisthesis. 14.3% (n = 5) had 
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between Bechet’s Disease (BD) and relapsing polychondritis (RP). 
BD is an inflammatory disease characterized by recurrent oral aph-
thous ulcers, genital ulcers, pathergy, neurological, vascular manifes-
tations. RP, an autoimmune disorder characterized by widespread, 
destructive, inflammatory lesions of cartilaginous structures, includ-
ing ear, nose, larynx, trachea, bronchi, peripheral joints, eye, heart, 
and skin. Here we examine further the differences and similarities 
between these two syndromes and the clinical implication of MAGIC 
syndrome. 
 Methods: A 44- year- old Caucasian- gentlemen, with a history of 
RP, seen by a rheumatology clinic. Information gathered is through 
medical record review. He was diagnosed with BD at the age of 42. 
His BD was characterized with oral ulcers, polyarthritis, neurologic/
vascular lesions. Neurological symptoms included gait difficulties, 
dizziness, seizure. Vascular lesions included peripheral artery aneu-
rysms. There was no documented treatment in this patient’s case. 
Case description limited by available information. 
 Results: Diagnosis is done using the International Criteria of Bechet’s 
Disease (ICBD) which assigns 2- points each to ocular lesions and 
genital and oral aphthosis, 1- point to vascular, skin, and neurological 
manifestations and pathergy. A score of 4 or more is considered BD. 
Clinicians may see overlap of signs/symptoms with RP. Diagnostic 
criteria for RP include three or more of the following criteria: bi-
lateral auricular chondritis, nonerosive seronegative inflammatory 
polyarthritis, nasal chondritis, ocular inflammation, respiratory tract 
chondritis, cochlear/vestibular dysfunction. It has been postulated 
that autoimmunity to certain collagen could be the common mecha-
nism of both BD and RP. 
 Conclusion: Magic syndrome is thought to be an intermediate be-
tween BD and RP due to the overlaps of their features but there are 
still noted differences in their genetic predisposition and treatment. 
The relationship between these rare diseases requires further re-
search as they have implications in diagnosis and treatment for these 
conditions. 
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 Background: IgG4- related disease (IgG4- RD) is a novel entity of dis-
ease first recognised in 2003. It has wide spectrum of clinical mani-
festations, virtually affecting any organ. It’s epidemiology remain 
poorly described and treatment guideline still lacking. 
 Methods: We describe 7 IgG4RD cases diagnosed and treated in 2 
hospitals with rheumatologist in Sarawak from 2015 till 2020. 
 Results: 4 males and 3 females were reported with age during diag-
nosis ranging from 34 to 74 years old. 4 patients had tumefactive 
lesions (lacrimal gland and salivary gland swelling), 2 had obstruc-
tive symptoms (obstructive uropathy due to retroperitoneal fibro-
sis, obstructive jaundice secondary to autoimmune pancreatitis) 
and 1 had renal failure and proteinuria as presenting symptoms. 
Time taken from onset of symptoms to diagnosis range from 8 
months to 23 years. In all cases, histopathological findings were 
the prompt towards diagnosis of IgG4- RD. All patients fulfilled the 
ACR- EULAR classification criteria whereas only 3 met the 2010 
JCR comprehensive diagnostic criteria, due to lack of IgG4 level in 
others. All patients showed rapid response to steroid therapy, com-
plete resolution of salivary gland swelling were seen in 3 months, 
stent removal in those with obstructive symptoms were achieved in 
6 months whereas resolution of proteinuria was seen in 2 months. 
All remained in remission currently with or without treatment. 
Initial dose of prednisolone used ranged from 0.2 to 0.6mg/kg/day, 
all with good effect. 
 Conclusion: IgG4- RD is indolent but often highly destructive. It is 
treatable and if diagnosed early, damage is potentially reversible. In 
terms of diagnosis, we feel that the ACR- EULAR classification cri-
teria is more practical compared to the JCR criteria in places where 
resources are limited and laboratory testing of serum IgG4 level is 
not available. Good awareness and high index of suspicion among 
clinicians, radiologists and pathologists are thus essential in timely 
diagnosis and prompt treatment of IgG4- RD. 
 Avascular necrosis in rheumatology 
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 Background: Avascular necrosis (AVN) though not fatal, is a serious 
cause of morbidity for patients and its aetiology is multifactorial. 
This study aims to assess the pattern of AVN in Rheumatology. 
 Methods: A retrospective observational study was conducted 
in 9 patients diagnosed with AVN, with rheumatic diseases in 
Department of Rheumatology, Sri Ramachandra Institute of Higher 
Education and Research, Chennai from January 2018- December 
2020. 
 Results: All patients were female and mean age was 23.3 years 
(14- 33 years).The primary rheumatic disease was Systemic Lupus 
Erythematosus (SLE) in 7 (77.7%), Dermatomyositis (DM) in 1 
(11.1%) and Overlap Syndrome in 1 (11.1%).71.4%(n = 5/7) had 
neuropsychiatric SLE (NPSLE). All patients presented with localis-
ing symptoms, after an average disease duration of 2 years (0.5- 6 
years).Average baseline SLEDAI 2K was 18.2 (12- 24). The femo-
ral head was the most common site of AVN in 77.7%(n = 7/9) fol-
lowed by distal femur in 33.3%(n = 3/9). Multifocal AVN was seen 
in 22.2%(n = 2/9) and bone infarct in 11.1%(n = 1/9). Ficat Stage II 
was reported in 42.8%(n = 3/7), Stage III in 28.5%(n = 2/7), Stage 
